Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith; Elena García-Martínez; Michael R. Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1526250

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith
, Elena García-Martínez
, Michael R. Pitter
, Jitka Fucikova
, Radek Spisek
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi

Memorial Sloan-Kettering Cancer Center
Hospital Morales Meseguer
Sotio
Charles University
Institut national de la santé et de la recherche médicale
Université Paris-Sud
Center of Clinical Investigations in Biotherapies of Cancer (CICBT)
Université Paris-Saclay
Université Paris Cité
Sorbonne Université
Centre de Recherche des Cordeliers
Karolinska Institutet
Assistance publique – Hôpitaux de Paris
Cornell University

Research output: Contribution to journal › Review article › peer-review

205 Scopus citations

Abstract

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

Original language	English
Article number	e1526250
Journal	Oncoimmunology
Volume	7
Issue number	12
DOIs	https://doi.org/10.1080/2162402X.2018.1526250
State	Published - Dec 2 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Ampligen®
Hiltonol®
SD-101
bacillus Calmette-Guérin
imiquimod
motolimod

Access to Document

10.1080/2162402X.2018.1526250

Cite this

@article{c5796f636ab74ca0a9e69ec5456016ee,

title = "Trial Watch: Toll-like receptor agonists in cancer immunotherapy",

abstract = "Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.",

keywords = "Ampligen{\textregistered}, Hiltonol{\textregistered}, SD-101, bacillus Calmette-Gu{\'e}rin, imiquimod, motolimod",

author = "Melody Smith and Elena Garc{\'i}a-Mart{\'i}nez and Pitter, \{Michael R.\} and Jitka Fucikova and Radek Spisek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor \& Francis Group, LLC.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/2162402X.2018.1526250",

language = "English",

volume = "7",

journal = "Oncoimmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

TY - JOUR

T1 - Trial Watch

T2 - Toll-like receptor agonists in cancer immunotherapy

AU - Smith, Melody

AU - García-Martínez, Elena

AU - Pitter, Michael R.

AU - Fucikova, Jitka

AU - Spisek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

AB - Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

KW - Ampligen®

KW - Hiltonol®

KW - SD-101

KW - bacillus Calmette-Guérin

KW - imiquimod

KW - motolimod

UR - https://www.scopus.com/pages/publications/85058033462

U2 - 10.1080/2162402X.2018.1526250

DO - 10.1080/2162402X.2018.1526250

M3 - Review article

C2 - 30524908

AN - SCOPUS:85058033462

SN - 2162-4011

VL - 7

JO - Oncoimmunology

JF - Oncoimmunology

IS - 12

M1 - e1526250

ER -

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this